What is selank, and what is it studied for?
Selank is the heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro, formula C33H57N11O9, mass 751.9: the natural tetrapeptide tuftsin extended with the same Pro-Gly-Pro tail used in semax. It was developed in Russia, where a nasal pharmaceutical form is registered, and is studied in rodent and cell models for effects on GABAergic gene expression and immune signalling. The material here is for in-vitro research only.
What is the structure of Selank?
Seven residues with free termini, two basic residues (lysine and arginine) and three prolines, giving a net positive charge at neutral pH and a rigid, protease-resistant tail. No cysteine, methionine or tryptophan, so it has no strong chromophore above 250 nm and no fast oxidation route. Mass 751.9 by the certificate's identity line.
| Identifier | Value |
|---|---|
| Molecular formula | C33H57N11O9 |
| Molecular weight | 751.9 g/mol |
| Residues | 7 |
| CAS number | 129954-34-3 |
| PubChem CID | 11765600 |
| Current lot | SEL10-0803 |
How is Selank thought to work?
The parent tetrapeptide tuftsin modulates phagocyte function. Selank's reported central effects are associated with changes in the expression of genes involved in GABAergic transmission in rodent brain, as described by Volkova and colleagues in 2016; a direct receptor target is not established.
Which research areas use Selank?
| Area | Typical models and endpoints |
|---|---|
| GABAergic gene expression | Transcript profiling in rodent brain regions after peptide exposure. |
| Immune signalling | Cytokine and phagocyte readouts descended from the tuftsin literature. |
| Behavioural pharmacology | Rodent anxiety-model paradigms in the Russian literature. |
| Analogue comparisons | Selank against semax and tuftsin in parallel assays. |
What does the published literature show?
Kozlovskaya et al. (2003) described selank among tuftsin-family short peptides in Neuroscience and Behavioral Physiology; Volkova et al. (Frontiers in Pharmacology, 2016) reported effects on GABA-related gene expression in rats. Clinical reports concern the registered Russian nasal product, not the material here. No FDA or EMA approval exists; research use is in-vitro and preclinical.
How is Selank handled in the laboratory?
Dissolves instantly in water. Stable in solution relative to most peptides in the catalogue because it lacks oxidation-prone residues; still aliquot and freeze. Low adsorption at micromolar concentrations; use low-binding tubes below that. Store lyophilized at minus 20 °C. The concentration table covers volumes and syringe units; the storage guide covers stability by compound class.
What does the current certificate show?
Lot SEL10-0803 tested at 99.83% purity by RP-HPLC (214 nm), identity confirmed by LC-MS/MS, endotoxin <0.05 EU/mL. The certificate is in the COA library and the lot number on the vial matches it. Sold as 10 mg per vial at $65, for laboratory research only.
Certificate history for Selank
Every certificate the library holds for this compound, newest first. A replaced lot stays listed so the history can be read; the certificate dataset reads all 114 together.
| Lot | Issued | Size | Identity | Purity | Content | Status |
|---|---|---|---|---|---|---|
| SEL10-0803 | Aug 17, 2026 | 10 mg | LC-MS/MS | 99.83% | 10.93 mg | Current |
| SEL10-0528 | Jun 17, 2026 | 10 mg | MALDI-MS | 99.8% | 10.56 mg | Replaced |
| SEL10-0318 | Apr 3, 2026 | 10 mg | MALDI-MS | 99.6% | 10.72 mg | Replaced |
Frequently asked questions
What is tuftsin?
The natural tetrapeptide Thr-Lys-Pro-Arg, a fragment of immunoglobulin G that stimulates phagocytosis. Selank is tuftsin plus Pro-Gly-Pro.
What does the current certificate show?
Lot SEL10-0803: identity by LC-MS/MS at 751.9, purity 99.83% by RP-HPLC at 214 nm, content 10.93 mg, endotoxin below 0.05 EU/mL. Issued 17 August 2026.
Why does selank keep better in solution than semax?
Selank has no methionine, so the oxidation route that degrades semax solutions does not apply. Both still benefit from aliquoting and freezing.
References
- Kozlovskaya MM, Kozlovskii II, Val'dman EA, Seredenin SB. Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. Neurosci Behav Physiol. 2003;33(9):853-860.
- Volkova A, Shadrina M, Kolomin T, et al. Selank administration affects the expression of some genes involved in GABAergic neurotransmission. Front Pharmacol. 2016;7:31.
- PubChem CID 11765600, Selank. National Library of Medicine. Read 2 October 2026.
Clinical results cited above describe regulated trials of pharmaceutical products and are given as context for research interest only. Nothing on this page describes or recommends use of the material sold here in humans or animals.
Selank 10 mg
$65 per vial
Lot SEL10-0803 · 99.83% RP-HPLC (214 nm) · certificate published
View productRelated
- Semax research guide · Semax 10 mg
- DSIP research guide · DSIP 5 mg
- DSIP: the nine-residue sequence, the 1977 rabbit experiments, the receptor nobody has found, and what a 5 mg certificate shows
- Selank + Semax blend: what the certificate for lot SEMSEL5-0803 shows, which peak is which, and how the molar ratio comes out
- Selank: the tuftsin analogue, its seven-residue sequence, and what a 10 mg certificate shows
- PE-22-28: the spadin fragment, the TREK-1 channel, and what a 10 mg certificate shows
- Glossary of certificate terms
